|Bid||0.0000 x 1000|
|Ask||1.9000 x 1800|
|Day's Range||1.5578 - 1.8000|
|52 Week Range||1.0400 - 2.0200|
|Beta (3Y Monthly)||0.36|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Over the last month the MYOS RENS Technology Inc. (NASDAQ:MYOS) has been much stronger than before, rebounding by 34...
Yesterday, MYOS Rens Technology (MYOS) announced topline results from a study conducted at the University of California, Berkeley which further supports the role of (their proprietary) Fortetropin in the promotion of muscle growth. This study focused specifically on older adults – namely those between the ages of 60 and 75 years – and measured the change in the ‘fractional synthetic rate’ (FSR) of muscle proteins. FSR, in this context, essentially describes the speed at which the body builds new muscle proteins (i.e.
Q1 2019 Update: MYOS Canine Sales Jump, Initial Reviews are Highly Encouraging. MYOS RENS Technology Inc (MYOS) reported Q1’19 financial results and provided a business update. Revenue from MYOS Canine nearly doubled from Q4’18.
MYOS RENS Technology (MYOS) reported Q4’18 financial results and provided a business update. Revenue from both Yolked and MYOS Canine Muscle Formula, their two lead products which launched in April and June (2018), respectively, reached new quarterly highs in the period.
CEO of Myos Rens Technology Inc (NASDAQ:MYOS) Joseph Mannello bought 171,233 shares of MYOS on 03/27/2019 at an average price of $1.46 a share.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! If you're interested in MYOS RENS Technology Inc. (NASDAQ:MYOS), thenRead More...
Last week MYOS RENS Technology Inc (MYOS) announced positive results of a study conducted at Kansas St. University evaluating the ability of their canine Fortetropin formula to reduce muscle loss in dogs following tibial-plateau leveling osteotomy, or TPLO (i.e. As the leg must be immobilized for weeks following TPLO, muscle loss is a common complication of the procedure. Muscle atrophy is typically evident within two weeks following surgery.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...
Myos, a biotherapeutics and bionutrition company, said Vitamin Shoppe Inc (NYSE: VSI) has agreed to distribute Yolked, a product intended to build lean muscle. Prior to the deal, Yolked was available only to collegiate athletic programs, according to Myos.
Q3 2018 Update: MYOS Canine Initial Sales and Add’l Distribution. MYOS RENS Technology Inc (MYOS) reported Q3’18 financial results and provided a business update. Near-term catalysts include expanded availability of both MYOS Canine, including through Miller Veterinary Supply East, Amazon.com (where it is designated an “Amazon’s Choice product) and MYOS’ own dedicated website, as well as Yolked, which is expected to soon be available to the general public (in addition to a growing list of universities).
If you’re interested in MYOS RENS Technology Inc (NASDAQ:MYOS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stockRead More...
MYOS RENS Technology (NASDAQMYOS) reported Q2 '18 financial results and provided a business update. Revenue from Qurr, MYOS' consumer-focused Fortetropin-based products (puddings, powders and shakes) which launched in April 2017, was $56k and $113k in the three and six months ending June 30, 2018. While Qurr continues to be the majority contributor to the company's top-line, accounting for nearly 80% of total revenue through the first half of the year, its proportional contribution will likely moderate as MYOS' new products gain traction.